RW Baird Ups CBST To Outperform
Analysts at RW Baird upgrade Cubist Pharmaceuticals Inc (NASDAQ: CBST) from “neutral” to “outperform.” The target price for CBST has been raised from $22 to $35.
CBST shares rose 0.44% to close at $25.25 yesterday.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted-In: RW BairdUpgrades Price Target Analyst Ratings